Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.32 |
| ▸ | F10 | P00742 | 6/20 | 0.32 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.31 |
| ▸ | CD69 | Q07108 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TEC | P42680 | 1/20 | 0.30 |
| ▸ | TXK | P42681 | 1/20 | 0.30 |
| ▸ | BMX | P51813 | 1/20 | 0.30 |
| ▸ | ITK | Q08881 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL797271 | 1.00 | BTK (0.32) | BTKF10MAP3K12CD69CYP3A4 | |
| Hydrochloric Acid SCHEMBL2598531 | 0.99 | BTK (0.31) | BTKF10MAP3K12CD69 | |
| SCHEMBL797270 | 0.88 | FPR2 (0.35) | BTKF10CD69CYP3A4TEC | |
| SCHEMBL796253 | 0.87 | F10 (0.35) | BTKF10CYP3A4 | |
| SCHEMBL796254 | 0.87 | F10 (0.35) | BTKF10CYP3A4 | |
| Hydrochloric Acid SCHEMBL2598528 | 0.87 | FPR2 (0.34) | BTKF10CD69CYP3A4TEC | |
| Hydrochloric Acid SCHEMBL790095 | 0.87 | GPR119 (0.35) | BTKF10CYP3A4 | |
| SCHEMBL797321 | 0.83 | F10 (0.36) | BTKF10 | |
| SCHEMBL797322 | 0.83 | F10 (0.36) | BTKF10 | |
| Hydrochloric Acid SCHEMBL796773 | 0.82 | F10 (0.35) | BTKF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616074-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | Array Biopharma, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130184257-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2013-07-18 | — | — | US | disclosed |
| WO-2012037393-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184257-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | GPR119, GPR139, GPR180 | BTK 3212/4885F10 3806/4885MAP3K12 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.